Dermatology Times November 2024 Recap

Clearances, Approvals, Updates, and Recommendations

FDA Approves Journey Medical’s DFD-29 for Rosacea

The minocycline hydrochloride extended release capsules (40 mg) represent a new standard of care for patients with rosacea.

PDUFA Date for Tapinarof 1% Cream in Atopic Dermatitis Pushed to 2025

The target action review date has been pushed to March 12, 2025.

FDA Sets PDUFA Date, Accepts BLA Submission for Pz-cel in Epidermolysis Bullosa

Abeona's pz-cel has been granted a April 29, 2025, PDUFA date.

Delgocitinib Approved for Adults with Moderate to Severe CHE in Switzerland

Delgocitinib is indicated for adults with CHE who either do not respond to or cannot use topical corticosteroids.

FDA Accepts sBLA of Dupilumab for the Treatment of Chronic Spontaneous Urticaria

The target action date for the FDA decision is April 18, 2025.

FDA Approves Bimekizumab for Adults with Moderate to Severe HS

The drug is the first FDA-approved treatment for moderate to severe HS that selectively inhibits both IL-17A and IL-17F.

Big Studies and Big Data

Rademikibart Differentiates From Dupilumab With Optimized IL-4Rα Inhibition and Enhanced Binding Stability

Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.

VYN201 for Vitiligo: Phase 1b Study Confirms Safety

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

Clascoterone Cream 1% Deemed Stable When Combined With Other Topical Acne Treatments

A poster presented at the 2024 SDPA Fall Conference demonstrated that clascoterone cream remains stable when paired with commonly prescribed acne topicals, supporting its role in multimodal therapy.

Market and Pharma News, Drug Watch

Dermatology Times' Parent Company, MJH Life Sciences, Acquires Revolutionizing Atopic Dermatitis (RAD) Conference

RAD will join MJH's multichannel model, enhancing its educational impact in atopic dermatitis, alopecia areata, vitiligo, and eczema.

ILDS Honors Young Dermatologists Receiving International Achievement Award

The ILDS has named 6 young dermatologists from around the world as recipients of the 2025 Young Dermatologists International Achievement Awards for their contributions to dermatology.

Concerto Biosciences Doses First Participant in Phase 1 Trial of ENS-002, a Microbiome-Based Therapy for Atopic Dermatitis

ENS-002 targets S. aureus in atopic dermatitis.

Soligenix Launches European Advisory Board for Phase 3 HyBryte CTCL Trial

The study is set to begin enrollment later this year.

Protagonist Introduces Oral Peptide IL-17 Antagonist PN-881

According to the company, comparative tests revealed PN-881 surpasses or matches the efficacy of current injectable IL-17 therapies.

Strides for Skin Health Equity

SCAN Project Empowers Cosmetologists in Early Skin Cancer Detection

Bree Vanleeuwen, PA-C, and Jim Sutton, PA-C, discussed the Skin Cancer Awareness project—a unique initiative to train cosmetologists and hairdressers to recognize suspicious skin lesions and refer clients for dermatologic evaluation.

CAB Gel Shows Promising Results for Hispanic Patients with Acne

The study demonstrated significant reductions in inflammatory and non-inflammatory lesions for Hispanic patients using CAB gel.

Study Highlights Gaps in Diverse Skin Representation in Nursing Textbooks

The study calls for improved diversity in clinical training materials to help future clinicians better recognize conditions on darker skin.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.